Annabelle Volgman
Concepts (330)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atrial Fibrillation | 22 | 2022 | 197 | 8.250 |
Why?
| Cardiovascular Diseases | 16 | 2021 | 410 | 4.180 |
Why?
| Stroke | 19 | 2022 | 367 | 3.980 |
Why?
| Anticoagulants | 6 | 2022 | 151 | 2.090 |
Why?
| Heart Failure | 7 | 2022 | 232 | 2.010 |
Why?
| Healthcare Disparities | 6 | 2020 | 82 | 1.970 |
Why?
| Coronary Artery Disease | 8 | 2022 | 159 | 1.960 |
Why?
| Female | 68 | 2022 | 18253 | 1.820 |
Why?
| Sex Factors | 17 | 2021 | 542 | 1.780 |
Why?
| Humans | 86 | 2022 | 31481 | 1.700 |
Why?
| Myocardial Infarction | 9 | 2022 | 187 | 1.620 |
Why?
| Exercise | 7 | 2022 | 454 | 1.590 |
Why?
| Risk Factors | 28 | 2022 | 2664 | 1.530 |
Why?
| Risk Assessment | 14 | 2022 | 806 | 1.480 |
Why?
| Hospital Mortality | 6 | 2021 | 192 | 1.430 |
Why?
| Hospitalization | 8 | 2021 | 359 | 1.410 |
Why?
| Life Style | 8 | 2020 | 219 | 1.400 |
Why?
| Women's Health | 4 | 2020 | 228 | 1.390 |
Why?
| Cardiology | 4 | 2021 | 102 | 1.330 |
Why?
| Primary Prevention | 4 | 2022 | 53 | 1.330 |
Why?
| Physicians, Women | 3 | 2022 | 15 | 1.280 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 81 | 1.230 |
Why?
| Aged | 38 | 2022 | 10295 | 1.210 |
Why?
| Sex Characteristics | 5 | 2021 | 128 | 1.200 |
Why?
| Myocardial Ischemia | 3 | 2021 | 63 | 1.190 |
Why?
| Catheter Ablation | 3 | 2022 | 76 | 1.180 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 31 | 1.120 |
Why?
| Adrenergic beta-Antagonists | 2 | 2020 | 45 | 1.120 |
Why?
| Health Status Disparities | 4 | 2019 | 70 | 1.110 |
Why?
| Arrhythmias, Cardiac | 6 | 2019 | 158 | 1.090 |
Why?
| Defibrillators, Implantable | 3 | 2021 | 31 | 1.060 |
Why?
| Anti-Arrhythmia Agents | 7 | 2022 | 101 | 1.030 |
Why?
| Male | 41 | 2022 | 17583 | 1.020 |
Why?
| United States | 23 | 2021 | 2539 | 0.950 |
Why?
| American Heart Association | 3 | 2021 | 39 | 0.950 |
Why?
| Echocardiography, Doppler, Color | 2 | 2019 | 15 | 0.940 |
Why?
| Middle Aged | 30 | 2021 | 11209 | 0.900 |
Why?
| Coronavirus | 1 | 2021 | 2 | 0.870 |
Why?
| Pregnancy Complications, Cardiovascular | 5 | 2021 | 16 | 0.860 |
Why?
| Electrocardiography | 7 | 2015 | 209 | 0.850 |
Why?
| Breast Neoplasms | 3 | 2021 | 442 | 0.840 |
Why?
| Length of Stay | 4 | 2020 | 377 | 0.810 |
Why?
| Chest Pain | 1 | 2020 | 23 | 0.810 |
Why?
| Endothelium | 1 | 2020 | 15 | 0.800 |
Why?
| Social Media | 1 | 2021 | 35 | 0.790 |
Why?
| Quality of Life | 5 | 2021 | 663 | 0.790 |
Why?
| Patient Care Management | 2 | 2021 | 18 | 0.770 |
Why?
| Brain Ischemia | 1 | 2021 | 122 | 0.770 |
Why?
| Vascular Diseases | 1 | 2020 | 59 | 0.760 |
Why?
| Takotsubo Cardiomyopathy | 1 | 2019 | 20 | 0.750 |
Why?
| Myxoma | 1 | 2019 | 7 | 0.750 |
Why?
| Cardiomyopathies | 1 | 2019 | 39 | 0.750 |
Why?
| Heart Neoplasms | 1 | 2019 | 21 | 0.740 |
Why?
| Heart Failure, Diastolic | 1 | 2018 | 2 | 0.730 |
Why?
| Comorbidity | 5 | 2021 | 562 | 0.720 |
Why?
| Women's Health Services | 1 | 2018 | 12 | 0.720 |
Why?
| Culturally Competent Care | 1 | 2018 | 10 | 0.710 |
Why?
| Heart Diseases | 1 | 2020 | 102 | 0.700 |
Why?
| Age Factors | 8 | 2021 | 943 | 0.700 |
Why?
| Prevalence | 6 | 2020 | 544 | 0.700 |
Why?
| Delivery of Health Care, Integrated | 1 | 2018 | 30 | 0.700 |
Why?
| Ambulatory Care Facilities | 1 | 2018 | 42 | 0.700 |
Why?
| Emigrants and Immigrants | 1 | 2018 | 25 | 0.690 |
Why?
| Warfarin | 3 | 2016 | 60 | 0.680 |
Why?
| Coronavirus Infections | 1 | 2020 | 97 | 0.680 |
Why?
| Pneumonia, Viral | 1 | 2020 | 102 | 0.680 |
Why?
| Heart Ventricles | 1 | 2019 | 218 | 0.670 |
Why?
| Atherosclerosis | 1 | 2018 | 57 | 0.670 |
Why?
| Antineoplastic Agents | 1 | 2020 | 274 | 0.640 |
Why?
| Lipoprotein(a) | 1 | 2016 | 10 | 0.600 |
Why?
| Cognition | 3 | 2020 | 1206 | 0.590 |
Why?
| Dyslipidemias | 1 | 2016 | 26 | 0.590 |
Why?
| Prognosis | 7 | 2021 | 1028 | 0.570 |
Why?
| Electrodes | 1 | 2015 | 16 | 0.570 |
Why?
| Treatment Outcome | 12 | 2022 | 3910 | 0.570 |
Why?
| Diabetes Mellitus | 3 | 2022 | 150 | 0.570 |
Why?
| Secondary Prevention | 3 | 2022 | 67 | 0.550 |
Why?
| Cost of Illness | 1 | 2015 | 65 | 0.550 |
Why?
| Social Support | 1 | 2016 | 224 | 0.530 |
Why?
| Electric Countershock | 6 | 2020 | 21 | 0.510 |
Why?
| Patient Readmission | 3 | 2019 | 129 | 0.510 |
Why?
| Hypertension | 6 | 2022 | 283 | 0.500 |
Why?
| Aspirin | 2 | 2020 | 90 | 0.500 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 230 | 0.500 |
Why?
| Magnetic Resonance Imaging | 1 | 2019 | 1273 | 0.490 |
Why?
| Aged, 80 and over | 9 | 2021 | 5234 | 0.480 |
Why?
| Adult | 14 | 2022 | 9779 | 0.450 |
Why?
| Pregnancy | 7 | 2021 | 457 | 0.440 |
Why?
| Patient Acceptance of Health Care | 1 | 2012 | 85 | 0.440 |
Why?
| Coronary Angiography | 3 | 2020 | 106 | 0.430 |
Why?
| Cardiovascular System | 2 | 2021 | 10 | 0.410 |
Why?
| Acute Kidney Injury | 2 | 2021 | 64 | 0.400 |
Why?
| Cardiac Resynchronization Therapy Devices | 2 | 2019 | 10 | 0.390 |
Why?
| Cardiovascular Agents | 2 | 2021 | 34 | 0.390 |
Why?
| Aortic Valve Stenosis | 2 | 2020 | 28 | 0.390 |
Why?
| Transcatheter Aortic Valve Replacement | 2 | 2020 | 28 | 0.390 |
Why?
| Hospital Costs | 2 | 2020 | 73 | 0.370 |
Why?
| Feasibility Studies | 2 | 2020 | 281 | 0.370 |
Why?
| Practice Guidelines as Topic | 3 | 2021 | 389 | 0.340 |
Why?
| Ventricular Fibrillation | 2 | 2021 | 27 | 0.330 |
Why?
| Heart Atria | 2 | 2019 | 89 | 0.320 |
Why?
| Retrospective Studies | 8 | 2021 | 3591 | 0.320 |
Why?
| Administration, Oral | 3 | 2016 | 164 | 0.290 |
Why?
| Health Status | 2 | 2018 | 249 | 0.290 |
Why?
| Sex Distribution | 3 | 2019 | 89 | 0.280 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2020 | 375 | 0.280 |
Why?
| Antihypertensive Agents | 2 | 2020 | 91 | 0.270 |
Why?
| Hemorrhage | 5 | 2020 | 90 | 0.270 |
Why?
| Risk Adjustment | 2 | 2021 | 14 | 0.270 |
Why?
| Hospital Charges | 2 | 2020 | 23 | 0.260 |
Why?
| African Americans | 3 | 2016 | 818 | 0.260 |
Why?
| Incidence | 4 | 2020 | 829 | 0.260 |
Why?
| Logistic Models | 3 | 2021 | 479 | 0.250 |
Why?
| Obesity | 4 | 2020 | 338 | 0.250 |
Why?
| Illinois | 2 | 2021 | 266 | 0.250 |
Why?
| Leadership | 2 | 2022 | 109 | 0.250 |
Why?
| Aortic Valve | 2 | 2020 | 35 | 0.250 |
Why?
| Cardiotoxicity | 2 | 2020 | 9 | 0.250 |
Why?
| Age Distribution | 2 | 2020 | 110 | 0.250 |
Why?
| Cost-Benefit Analysis | 2 | 2022 | 153 | 0.240 |
Why?
| Morbidity | 2 | 2019 | 71 | 0.240 |
Why?
| Young Adult | 3 | 2020 | 2277 | 0.240 |
Why?
| Health Promotion | 2 | 2016 | 186 | 0.230 |
Why?
| Polypharmacy | 1 | 2022 | 9 | 0.230 |
Why?
| Vitamin K | 1 | 2022 | 11 | 0.230 |
Why?
| Sotalol | 1 | 2021 | 10 | 0.230 |
Why?
| Cardiac Electrophysiology | 1 | 2021 | 3 | 0.220 |
Why?
| Coronary Circulation | 2 | 2020 | 49 | 0.220 |
Why?
| Troponin | 1 | 2021 | 11 | 0.220 |
Why?
| Shock, Cardiogenic | 1 | 2021 | 10 | 0.220 |
Why?
| Diagnostic Techniques, Cardiovascular | 1 | 2021 | 3 | 0.220 |
Why?
| Sexism | 1 | 2021 | 8 | 0.220 |
Why?
| Water-Electrolyte Imbalance | 1 | 2021 | 3 | 0.220 |
Why?
| Societies, Medical | 2 | 2020 | 209 | 0.220 |
Why?
| Hormones | 1 | 2021 | 19 | 0.220 |
Why?
| Atrial Appendage | 1 | 2022 | 47 | 0.220 |
Why?
| Death, Sudden, Cardiac | 1 | 2021 | 30 | 0.210 |
Why?
| Overweight | 1 | 2022 | 67 | 0.210 |
Why?
| Adolescent | 2 | 2020 | 2667 | 0.210 |
Why?
| Women's Rights | 1 | 2021 | 3 | 0.210 |
Why?
| National Institutes of Health (U.S.) | 1 | 2021 | 33 | 0.210 |
Why?
| Alcohol Drinking | 1 | 2022 | 86 | 0.210 |
Why?
| Pacemaker, Artificial | 2 | 2019 | 32 | 0.210 |
Why?
| Weight Loss | 1 | 2022 | 114 | 0.210 |
Why?
| Signal Processing, Computer-Assisted | 2 | 1998 | 44 | 0.210 |
Why?
| Angioplasty | 1 | 2020 | 17 | 0.210 |
Why?
| Sleep Apnea, Obstructive | 1 | 2022 | 72 | 0.210 |
Why?
| Health Expenditures | 1 | 2020 | 20 | 0.210 |
Why?
| Hyperlipidemias | 1 | 2020 | 29 | 0.210 |
Why?
| Career Choice | 1 | 2021 | 33 | 0.210 |
Why?
| Physician-Patient Relations | 1 | 2021 | 47 | 0.210 |
Why?
| Cross-Sectional Studies | 4 | 2017 | 986 | 0.210 |
Why?
| Heart Valve Diseases | 1 | 2020 | 32 | 0.210 |
Why?
| Peripheral Arterial Disease | 1 | 2020 | 21 | 0.200 |
Why?
| Disease Outbreaks | 1 | 2021 | 87 | 0.200 |
Why?
| Postoperative Hemorrhage | 1 | 2020 | 31 | 0.200 |
Why?
| Periodicals as Topic | 1 | 2021 | 46 | 0.200 |
Why?
| Myocardial Revascularization | 1 | 2020 | 25 | 0.200 |
Why?
| Postnatal Care | 1 | 2020 | 9 | 0.200 |
Why?
| Delivery, Obstetric | 1 | 2020 | 15 | 0.200 |
Why?
| Accidental Falls | 1 | 2022 | 118 | 0.200 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 4 | 0.200 |
Why?
| Colchicine | 1 | 2020 | 9 | 0.200 |
Why?
| Protective Factors | 1 | 2020 | 19 | 0.200 |
Why?
| Social Class | 1 | 2020 | 71 | 0.200 |
Why?
| Endovascular Procedures | 1 | 2020 | 79 | 0.190 |
Why?
| After-Hours Care | 1 | 2019 | 1 | 0.190 |
Why?
| Income | 1 | 2020 | 77 | 0.190 |
Why?
| Prostatic Neoplasms | 1 | 2021 | 122 | 0.190 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2020 | 49 | 0.190 |
Why?
| Odds Ratio | 2 | 2020 | 327 | 0.190 |
Why?
| Global Health | 1 | 2019 | 60 | 0.190 |
Why?
| Radiation Injuries | 1 | 2020 | 44 | 0.190 |
Why?
| Thrombolytic Therapy | 1 | 2020 | 85 | 0.190 |
Why?
| Cardiac Resynchronization Therapy | 1 | 2019 | 23 | 0.190 |
Why?
| Up-Regulation | 2 | 2021 | 220 | 0.190 |
Why?
| Multimodal Imaging | 1 | 2019 | 30 | 0.190 |
Why?
| Health Behavior | 1 | 2020 | 177 | 0.190 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 378 | 0.190 |
Why?
| Heart | 1 | 2019 | 110 | 0.180 |
Why?
| Treatment Refusal | 1 | 2018 | 13 | 0.180 |
Why?
| Asia, Western | 1 | 2018 | 2 | 0.180 |
Why?
| Indian Ocean Islands | 1 | 2018 | 2 | 0.180 |
Why?
| Procainamide | 1 | 1998 | 20 | 0.180 |
Why?
| Heart Transplantation | 1 | 1998 | 50 | 0.180 |
Why?
| Atrial Flutter | 1 | 1998 | 13 | 0.180 |
Why?
| Graft Rejection | 1 | 1998 | 84 | 0.170 |
Why?
| Intensive Care Units | 1 | 2021 | 316 | 0.170 |
Why?
| Tachycardia | 2 | 2021 | 43 | 0.170 |
Why?
| Walking | 1 | 2020 | 249 | 0.170 |
Why?
| Pandemics | 1 | 2020 | 203 | 0.170 |
Why?
| Sulfonamides | 1 | 1998 | 64 | 0.170 |
Why?
| Reproducibility of Results | 3 | 2017 | 886 | 0.170 |
Why?
| Memory Disorders | 1 | 2019 | 181 | 0.170 |
Why?
| Diagnosis, Differential | 1 | 2019 | 467 | 0.170 |
Why?
| Inpatients | 1 | 2019 | 154 | 0.160 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 193 | 0.160 |
Why?
| Coronary Disease | 2 | 2020 | 98 | 0.160 |
Why?
| Diet Surveys | 1 | 2017 | 26 | 0.160 |
Why?
| Patient Discharge | 1 | 2018 | 163 | 0.160 |
Why?
| Pyridones | 1 | 2016 | 19 | 0.160 |
Why?
| Nutrition Assessment | 1 | 2017 | 53 | 0.160 |
Why?
| Thiazoles | 1 | 2016 | 38 | 0.160 |
Why?
| Evidence-Based Practice | 1 | 2017 | 86 | 0.160 |
Why?
| Evidence-Based Medicine | 1 | 2018 | 239 | 0.160 |
Why?
| Pyridines | 1 | 2016 | 50 | 0.160 |
Why?
| Neoplasms | 1 | 2020 | 280 | 0.160 |
Why?
| Coronary Vessels | 2 | 2021 | 52 | 0.150 |
Why?
| Patient Selection | 2 | 2020 | 264 | 0.150 |
Why?
| Georgia | 1 | 2016 | 16 | 0.150 |
Why?
| Diet, Mediterranean | 1 | 2017 | 57 | 0.150 |
Why?
| Dementia | 1 | 2022 | 545 | 0.150 |
Why?
| Sensitivity and Specificity | 2 | 2015 | 580 | 0.150 |
Why?
| Cholesterol, LDL | 1 | 2016 | 46 | 0.150 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2016 | 62 | 0.150 |
Why?
| Pyrazoles | 1 | 2016 | 55 | 0.150 |
Why?
| Health Surveys | 1 | 2016 | 102 | 0.150 |
Why?
| Self Efficacy | 1 | 2016 | 65 | 0.150 |
Why?
| Miniaturization | 1 | 2015 | 3 | 0.140 |
Why?
| Preventive Health Services | 1 | 2015 | 16 | 0.140 |
Why?
| Equipment Design | 2 | 2015 | 198 | 0.140 |
Why?
| Chicago | 2 | 2016 | 955 | 0.140 |
Why?
| Asian Americans | 1 | 2015 | 53 | 0.140 |
Why?
| Equipment Failure Analysis | 1 | 2015 | 116 | 0.140 |
Why?
| Heart Rate | 2 | 2009 | 161 | 0.140 |
Why?
| Smoking | 2 | 2018 | 202 | 0.130 |
Why?
| Needs Assessment | 1 | 2013 | 50 | 0.120 |
Why?
| Cardiac Pacing, Artificial | 2 | 1992 | 63 | 0.120 |
Why?
| Drug Monitoring | 1 | 2012 | 29 | 0.120 |
Why?
| Activities of Daily Living | 1 | 2016 | 495 | 0.120 |
Why?
| Heart Conduction System | 1 | 1992 | 29 | 0.120 |
Why?
| Data Collection | 1 | 2012 | 120 | 0.110 |
Why?
| Cohort Studies | 3 | 2022 | 2014 | 0.100 |
Why?
| Echocardiography | 3 | 2019 | 197 | 0.100 |
Why?
| Percutaneous Coronary Intervention | 2 | 2020 | 25 | 0.100 |
Why?
| Motor Activity | 1 | 2013 | 397 | 0.100 |
Why?
| Coronary Artery Bypass | 2 | 2020 | 75 | 0.100 |
Why?
| Survival Rate | 2 | 2019 | 465 | 0.090 |
Why?
| Databases, Factual | 2 | 2019 | 391 | 0.080 |
Why?
| Azetidines | 1 | 2006 | 4 | 0.080 |
Why?
| Benzylamines | 1 | 2006 | 15 | 0.080 |
Why?
| Body Mass Index | 2 | 2020 | 458 | 0.070 |
Why?
| Severity of Illness Index | 2 | 2021 | 1240 | 0.070 |
Why?
| Time Factors | 3 | 2021 | 1902 | 0.070 |
Why?
| Endpoint Determination | 1 | 2004 | 31 | 0.070 |
Why?
| Postoperative Complications | 2 | 2020 | 1083 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2019 | 2028 | 0.060 |
Why?
| Registries | 2 | 2022 | 214 | 0.060 |
Why?
| Flecainide | 1 | 2021 | 13 | 0.060 |
Why?
| Microcirculation | 1 | 2021 | 40 | 0.060 |
Why?
| Double-Blind Method | 2 | 2006 | 559 | 0.060 |
Why?
| Prospective Studies | 2 | 1998 | 1934 | 0.060 |
Why?
| Ischemia | 1 | 2021 | 35 | 0.060 |
Why?
| Peripartum Period | 1 | 2021 | 3 | 0.050 |
Why?
| Pregnancy, High-Risk | 1 | 2021 | 3 | 0.050 |
Why?
| Chlorides | 1 | 2021 | 27 | 0.050 |
Why?
| Diuretics | 1 | 2021 | 16 | 0.050 |
Why?
| Recurrence | 2 | 2006 | 389 | 0.050 |
Why?
| Health Services Research | 1 | 2021 | 45 | 0.050 |
Why?
| Sodium | 1 | 2021 | 81 | 0.050 |
Why?
| Education, Medical | 1 | 2021 | 45 | 0.050 |
Why?
| Amputation | 1 | 2020 | 20 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2020 | 70 | 0.050 |
Why?
| Patient Preference | 1 | 2021 | 36 | 0.050 |
Why?
| Abortion, Spontaneous | 1 | 2020 | 9 | 0.050 |
Why?
| Fetal Growth Retardation | 1 | 2020 | 4 | 0.050 |
Why?
| Polycystic Ovary Syndrome | 1 | 2020 | 5 | 0.050 |
Why?
| Hypercholesterolemia | 1 | 2020 | 39 | 0.050 |
Why?
| Menopause, Premature | 1 | 2020 | 7 | 0.050 |
Why?
| Ischemic Attack, Transient | 1 | 2020 | 27 | 0.050 |
Why?
| Sleep Apnea, Central | 1 | 2000 | 26 | 0.050 |
Why?
| Lactation | 1 | 2021 | 77 | 0.050 |
Why?
| Case-Control Studies | 2 | 2000 | 687 | 0.050 |
Why?
| Health Care Costs | 1 | 2020 | 81 | 0.050 |
Why?
| Radiotherapy | 1 | 2020 | 65 | 0.050 |
Why?
| Attitude to Health | 1 | 2020 | 117 | 0.050 |
Why?
| Curriculum | 1 | 2021 | 158 | 0.050 |
Why?
| Costs and Cost Analysis | 1 | 2019 | 39 | 0.050 |
Why?
| Autoimmune Diseases | 1 | 2020 | 66 | 0.050 |
Why?
| Cause of Death | 1 | 2019 | 78 | 0.050 |
Why?
| Thrombectomy | 1 | 2019 | 51 | 0.050 |
Why?
| Multivariate Analysis | 1 | 2020 | 390 | 0.050 |
Why?
| Disease Management | 1 | 2020 | 147 | 0.050 |
Why?
| Psychology | 1 | 2018 | 24 | 0.040 |
Why?
| Health Services Needs and Demand | 1 | 2018 | 71 | 0.040 |
Why?
| Blood Pressure | 1 | 2020 | 260 | 0.040 |
Why?
| Heredity | 1 | 2018 | 8 | 0.040 |
Why?
| Diet, Western | 1 | 2017 | 8 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2020 | 224 | 0.040 |
Why?
| Quality Improvement | 1 | 2018 | 173 | 0.040 |
Why?
| Breast Feeding | 1 | 2018 | 177 | 0.040 |
Why?
| Waist Circumference | 1 | 2015 | 34 | 0.040 |
Why?
| Risk | 1 | 2016 | 228 | 0.040 |
Why?
| Decision Making | 1 | 2018 | 232 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 265 | 0.040 |
Why?
| Body Composition | 1 | 2016 | 81 | 0.040 |
Why?
| Body Weight | 1 | 2016 | 167 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 462 | 0.040 |
Why?
| Patient Compliance | 1 | 2016 | 200 | 0.030 |
Why?
| Wolff-Parkinson-White Syndrome | 1 | 1993 | 2 | 0.030 |
Why?
| Dextroamphetamine | 1 | 1993 | 6 | 0.030 |
Why?
| Social Networking | 1 | 2013 | 10 | 0.030 |
Why?
| Syncope | 1 | 1993 | 9 | 0.030 |
Why?
| Hypotension, Orthostatic | 1 | 1993 | 17 | 0.030 |
Why?
| Efficiency | 1 | 2013 | 21 | 0.030 |
Why?
| Albuterol | 1 | 1993 | 17 | 0.030 |
Why?
| Bradycardia | 1 | 1993 | 29 | 0.030 |
Why?
| Interviews as Topic | 1 | 2013 | 152 | 0.030 |
Why?
| Program Evaluation | 1 | 2013 | 153 | 0.030 |
Why?
| Tachycardia, Ventricular | 1 | 1992 | 35 | 0.030 |
Why?
| Cardiac Catheterization | 1 | 1992 | 110 | 0.030 |
Why?
| Asthma | 1 | 1993 | 182 | 0.030 |
Why?
| Animals | 1 | 2020 | 5312 | 0.020 |
Why?
| Estrogen Replacement Therapy | 1 | 2006 | 22 | 0.020 |
Why?
| Thromboembolism | 1 | 2006 | 37 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2006 | 178 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2006 | 390 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2004 | 456 | 0.020 |
Why?
| Electrocardiography, Ambulatory | 1 | 2000 | 18 | 0.010 |
Why?
| Bronchoscopy | 1 | 2000 | 38 | 0.010 |
Why?
| Respiration | 1 | 2000 | 37 | 0.010 |
Why?
| Anesthesia | 1 | 2000 | 29 | 0.010 |
Why?
| Tracheostomy | 1 | 2000 | 28 | 0.010 |
Why?
| Child | 1 | 2000 | 1572 | 0.010 |
Why?
| False Positive Reactions | 1 | 1993 | 40 | 0.010 |
Why?
| Administration, Inhalation | 1 | 1993 | 37 | 0.010 |
Why?
| Posture | 1 | 1993 | 92 | 0.010 |
Why?
| Action Potentials | 1 | 1993 | 143 | 0.010 |
Why?
| ROC Curve | 1 | 1992 | 153 | 0.010 |
Why?
| Analysis of Variance | 1 | 1992 | 364 | 0.010 |
Why?
|
|
Volgman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|